Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Pooja H. Rambhia, Barbara Reichert, Jeffrey F. Scott, Ashley N. Feneran, Jordan A. Kazakov, Kord Honda, Henry Koon, Meg R. Gerstenblith

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

Original languageEnglish (US)
Pages (from-to)1171-1181
Number of pages11
JournalInternational Journal of Clinical Oncology
Issue number10
StatePublished - Oct 1 2019


  • CTLA-4
  • Drug reactions
  • Immune checkpoint inhibitor
  • Melanoma
  • PD-1
  • Sarcoidosis-like granuloma

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of 'Immune checkpoint inhibitor-induced sarcoidosis-like granulomas'. Together they form a unique fingerprint.

Cite this